Skip to main content
. 2014 Apr 28;69(8):2164–2174. doi: 10.1093/jac/dku127

Figure 4.

Figure 4.

Effect of single-dose therapeutic treatment using BTA938 for an oseltamivir-resistant influenza A/Mississippi/03/2001 (H1N1) H275Y virus infection. Survival and body weight were monitored following a single treatment with BTA938 at the indicated doses, or twice daily for 5 days with zanamivir, beginning 4 h post-virus challenge. A significant difference in survival, compared with placebo, was observed for all the treatment groups (a). A significant difference in mean body weight was also observed for all treatment groups (b). ***P < 0.001.